F2G develops novel therapeutics for rare fungal infections, focusing on effective antifungals to provide more options for patients.

F2G | 6,800 followers on LinkedIn. The rare fungal disease company | F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway.

Biopharma C-suite Executive & Board Director┃ International P&L Management┃ Global Portfolio & Product Strategy, Commercialisation and Life Cycle…

Camilla Soenderby

Francesco Maria Lavino

Board Chair and Senior Advisor

Patrick Vink

CBO, F2G

Janelle R. Anderson

We're excited to present six posters at IDWeek 2024, showcasing our commitment to advancing novel antifungal treatments for invasive fungal infections! We look forward to connecting with peers in the #InfectiousDisease community to share insights and explore the latest advancements. See you at #IDWeek2024 🦠

As #FungalWeek24 concludes, revisit an insightful panel from last year’s #SXSW , featuring #InfectiousDisease experts from F2G, the Centers for Disease Control and Prevention , and academia, that highlights the challenges of fungal diseases, treatment complexities, and cross-resistance. Fungal infections are a growing global health issue. Watch the full panel to gain valuable insights on how we’re collectively hoping to address these challenges and advance the future of antifungal treatments: https://bit.ly/3MmYtSo

At F2G, we understand that the fight against fungal diseases requires more than just treatment innovation, it demands a comprehensive approach that considers the connection between human, animal, and environmental health. The "One Health" approach highlights the reality that fungal infections often stem from interactions within our ecosystems. By recognizing these links, we can better address the root causes of fungal diseases and advance more effective, sustainable treatments. This #FungalWeek24 , learn more from the Centers for Disease Control and Prevention about how fungal diseases are a One Health issue: https://bit.ly/3Z2lxNJ

Fungal diseases and antimicrobial resistance are on the rise globally, yet there has been limited treatment innovation to address these pressing challenges. This #FungalWeek24 , join us in raising awareness and education on these critical issues in the space. Learn more from the Centers for Disease Control and Prevention : https://bit.ly/3Z2lxNJ

We are thrilled to announce the close of a $100 million financing round, led by new investor AMR Action Fund with strong participation from new investor Intermediate Capital Group (ICG) Life Sciences and existing investors. The funds will be used to advance the late-stage development and commercialization of our novel antifungal drug candidate in the US. Read our new press with financing details on the media section of the F2G corporate website: https://bit.ly/3UlKDVE

At #SXSW2024 , our Chief Medical Officer, Dr. John Rex, joined a panel of infectious disease experts from government and academia to discuss the increasing threat of fungal infections, the effects of climate change, and addressing the global challenge. Read more in the Washington Examiner: https://bit.ly/3IyyuWd #FungiForumSXSW SXSW

We are proud to sponsor the 68th Annual Coccidioidomycosis Study Group because we believe in the power of knowledge exchange to drive innovation in the prevention and treatment of invasive fungal infections like Coccidioidomycosis (valley fever). We’ll share data through two oral presentations and a poster highlighting the progress being made by our team and partners. To learn more about what we are doing to address valley fever, visit: https://bit.ly/3THVE1h

Attending #SXSW2024 ? Our Chief Medical Officer, Dr. John Rex, will join a dynamic panel of fungal disease experts on Monday, March 11 at 4pm CST in Austin, TX. Don’t miss out on this engaging discussion—add it to your calendar now! https://brnw.ch/21wHHVN @sxsw #FungiForumSXSW

Attending #SXSW2024 ? Our Chief Medical Officer, Dr. John Rex, will join a dynamic panel of fungal disease experts on Monday, March 11 at 4pm CST in Austin, TX. Don’t miss out on this engaging discussion—add it to your calendar now! https://brnw.ch/21wHHsP @sxsw #FungiForumSXSW

Join us at #SXSW2024 on Monday, March 11 at 4pm CST, where a panel of infectious disease experts from F2G, government, and academia will explore challenges posed by fungi, treatment complexities, cross-resistance, and shared DNA hurdles in antifungal development. Learn more: https://brnw.ch/21wHF4y #FungiForumSXSW

F2G

COM:F2G

F2G

Analysis Not Available